Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
June 24 2021 - 4:05PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare
liver disease, today announced that it will participate in Piper
Sandler’s Virtual European Association for the Study of the Liver
(EASL) Takeaway Day on Monday, June 28, 2021, at 2:00 p.m. ET.
Chris Peetz, president and chief executive officer, and Pam Vig,
Ph.D., chief scientific officer, will participate in the fireside
chat.
Visit the event website to register. A replay will be available
within the Investor Relations section of Mirum’s website at
https://ir.mirumpharma.com/events-and-presentations.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. Mirum’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA
for maralixibat in the treatment of cholestatic pruritus in
patients with ALGS. The NDA has been accepted for priority review
by the FDA with a PDUFA action date of September 29, 2021.
Additionally, Mirum’s marketing authorization application for the
treatment of pediatric patients with PFIC2 has been accepted for
review (validated) by the European Medicines Agency. Mirum is also
developing volixibat, also an oral ASBT-inhibitor, in primary
sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and
primary biliary cholangitis. For more information, visit
MirumPharma.com.
To augment its pipeline in cholestatic liver disease, Mirum has
acquired the exclusive option to develop and commercialize gene
therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2,
respectively, from Vivet Therapeutics SAS, following preclinical
evaluation and investigational new drug-enabling studies.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210624005951/en/
Investors: Ian Clements, Ph.D. ir@mirumpharma.com
Media: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Sep 2023 to Sep 2024